Compare SMX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMX | CYCN |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Ireland | United States |
| Employees | 19 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 16.6M |
| IPO Year | N/A | N/A |
| Metric | SMX | CYCN |
|---|---|---|
| Price | $15.65 | $3.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 44.7K | 23.0K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $1.03 |
| 52 Week High | $490.00 | $8.48 |
| Indicator | SMX | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 66.61 |
| Support Level | $15.39 | $2.93 |
| Resistance Level | $17.72 | $8.48 |
| Average True Range (ATR) | 1.89 | 0.21 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 66.38 | 72.94 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.